Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression
Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression
The overall goals of this project are to assess the feasibility and impact of designing and
 implementing an at-home intervention aimed at preventing long-term cognitive decline and
 improving cognition in individuals currently at-risk for developing AD.
By the time Alzheimer's Dementia (AD) and related disorders are diagnosed, the brain has
 sustained substantial insult that limits the efficacy of current treatments. Preventive
 interventions are urgently needed but the majority of prevention studies require large
 numbers of participants, long follow-up periods, and frequent study visits. It is not
 feasible for many geriatric patients to attend clinics for treatment on a daily basis due to
 mobility and transportation restrictions, associated costs, and lack of rural clinic
 locations. Interventions delivered remotely, or administered within an individual's home,
 allow for preventative treatments to be made accessible to a wider range of individuals.
 Thus, the overall goals of this project are to assess the feasibility and impact of designing
 and implementing an at-home intervention aimed at preventing long-term cognitive decline and
 improving cognition in individuals currently at-risk for developing AD. These high-risk
 individuals that will be targeted in this proposal are: (1) older adults with Mild Cognitive
 Impairment (MCI), (2) older adults with Major Depressive Disorder (MDD), and (3) older adults
 with MCI and MDD.

 The proposed intervention combines cognitive remediation (CR) and non-invasive brain
 stimulation - transcranial Direct Current Stimulation (tDCS), to be delivered in the
 participants' home environment. Twenty couples (40 participants) will be recruited, with one
 member defined as the "patient" and the second member defined as the "caregiver" to the
 patient. These caregivers will facilitate the delivery of the study intervention (i.e.,
 CR+tDCS). Participants with a diagnosis of MCI or MDD or both, who have a caregiver, will
 receive open-label, active CR+tDCS over a period of 8 weeks. Both CR and tDCS have been shown
 to induce neuroplasticity and improve cognition. The aim of this pilot study is to assess the
 feasibility of delivering these combined interventions at home.
MCI Group

 Inclusion:

 1. Age > 60 (on day of randomization)

 2. DSM-IV criteria for Mild Neurocognitive Disorder ("MCI")

 3. Willingness to provide informed consent

 4. MADRS score of 10 or below

 5. Availability of a study partner who has regular contact with the participant

 6. Ability to read and communicate in English (with corrected vision and hearing, if
 needed)

 Exclusion:

 1. Met DSM-IV criteria for Major Depressive Episode in past 10 years

 2. Lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or OCD

 3. DSM-IV diagnosis of alcohol or other substances use disorder within the past 12 months

 4. High risk for suicide

 5. Significant neurological condition (e.g., stroke, seizure disorder, MS)

 6. Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)

 7. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within
 the past 6 weeks

 8. Participants taking anticonvulsants, and other psychotropic medication (see exception
 below) that cannot be safely tapered and discontinued. The following psychotropic
 medications are allowed if they have been taken at a stable dose for at least 4 weeks
 prior to study entry: zopiclone, trazadone, or a benzodiazepine; gabapentin,
 pregabalin, duloxetine, venlafaxine, or low-dose tricyclic antidepressants if
 prescribed for chronic pain.

 9. A pace-maker or other metal implants that would preclude safe use of tDCS.

 MDD Group

 Inclusion:

 1. Age ≥ 60 (on day of randomization)

 2. Meets DSM-IV criteria for one or more MDE(s)with:

 1. an offset of 2 months to 5 years from the screening visit date. It is not
 necessary for this (these) episode(s) to have received medical attention

 OR

 2. an offset of 5 years or more from the screening visit date. It is necessary that
 at least one MDE received medical attention (e.g., previously been on one or more
 antidepressant(s), saw a psychiatrist, primary care physician, or had a previous
 hospitalization). Also, the MDE must have occurred during the participant's adult
 life (i.e., at 18 years of age or older).

 3. MADRS score of 10 or below

 4. Willingness to provide informed consent

 5. Availability of a study partner who has regular contact with the participant

 6. Ability to read and communicate in English (with corrected vision and hearing, if
 needed)

 Exclusion:

 1. Meets DSM-IV criteria for Major Neurocognitive Disorder ("dementia")

 2. Lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or OCD

 3. DSM-IV diagnosis of alcohol or other substances use disorder within the past 12
 months.

 4. High risk for suicide.

 5. Significant neurological condition (e.g., stroke, seizure disorder, MS)

 6. Unstable medical illness (e.g., uncontrolled diabetes mellitus or hypertension)

 7. Participants taking anticonvulsants, and other psychotropic medication (see exception
 below) that cannot be safely tapered and discontinued. In addition to any
 antidepressant, the following psychotropic medications are allowed if they have been
 taken at a stable dose for at least 4 weeks prior to study entry: zopiclone,
 trazodone, or a benzodiazepine; and gabapentin or pregabalin if prescribed for chronic
 pain.

 8. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within
 the past 6 weeks.

 9. A pace-maker or other metal implants that would preclude safe use of tDCS.

 Facilitator Group

 Inclusion:

 1. Willingness to provide informed consent

 2. Ability to read and communicate in English (with corrected vision and hearing, if
 needed)

 Exclusion:

 3. Physical or medical illness that prevents participant from learning or administering
 CR + tDCS, as determined by the research team